Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial

Similar documents
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor

תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין

Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy

Why and How Should We Switch Clopidogrel to Prasugrel?

Belinda Green, Cardiologist, SDHB, 2016

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

QUT Digital Repository:

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management

TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

DECLARATION OF CONFLICT OF INTEREST

New antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

Updated and Guideline Based Treatment of Patients with STEMI

Supplementary Material to Mayer et al. A comparative cohort study on personalised

'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Non ST Elevation-ACS. Michael W. Cammarata, MD

P2Y 12 blockade. To load or not to load before the cath lab?

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.

Myth or Real? The Potential Serious Side Effects of Ticagrelor

Νεώτερα στην αντιαιμοπεταλιακή αγωγή

P 2 Y 12 Receptor Inhibitors

Otamixaban for non-st-segment elevation acute coronary syndrome

FastTest. You ve read the book now test yourself

ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium

When and how to combine antiplatelet agents and anticoagulant?

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

STEMI Presentation and Case Discussion. Case #1

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017

Robert Storey. Sheffield, United Kingdom

Controversies in Cardiac Pharmacology

Supplementary Table S1: Proportion of missing values presents in the original dataset

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen

bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Acute Coronary syndrome

Journal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS

Timing of Surgery After Percutaneous Coronary Intervention

Bivalirudin Clinical Trials Update Evidence and Future Perspectives

ACCP Cardiology PRN Journal Club. 24 May 2018

ISCHEMIC HEART DISEASE

On admission Acute extensive anterior STEMI

Session Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )

ACCP Cardiology PRN Journal Club

Dual Antiplatelet Therapy Made Practical

Horizon Scanning Centre November 2012

Disclosures. Research consulting with: Sanofi-Regeneron Pfizer The Medicines Company Astra Zeneca

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Is Cangrelor hype or hope in STEMI primary PCI?

Robert Storey. Sheffield, United Kingdom

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

Myocardial Infarction In Dr.Yahya Kiwan

Clopidogrel Use in ACS and PCI: Clinical Trial Update

The following is a transcript from a multimedia activity. Interactivity applies only when viewing the activity online.

Patient characteristics Intervention Comparison Length of followup

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

Guideline for STEMI. Reperfusion at a PCI-Capable Hospital

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Antithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

BRILINTA is a registered trademark of the AstraZeneca group of companies AstraZeneca /15

egfr > 50 (n = 13,916)

Study design: multicenter, randomized, open-label trial following a PROBE design

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013

Is the role of bivalirudin established?

(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris

Dual Antiplatelet Therapy: Time for a Paradigm Shift?

COME ORIENTARSI TRA I NUOVI. Maria Rosa Conte H. Mauriziano Torino

COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY

Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

INDIVIDUALIZED MEDICINE

A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment

Diagnostic, Technical and Medical

Transcription:

compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A Harrington, Diego Ardissino, Richard C. Becker, Christopher P. Cannon, Håkan Emanuelsson, Ariel Finkelstein, Steen Husted, Hugo Katus, Jan Kilhamn, Sylvia Olofsson, Robert F. Storey, Douglas Weaver, Lars Wallentin, for the PLATO study group *Unité INSERM U-698 Hôpital Bichat Claude Bernard Université Paris VII Denis Diderot Paris, France The PLATO trial was funded by AstraZeneca

(AZD 6140): an oral reversible P2Y 12 antagonist HO HO O N N N N N H N F is a cyclo-pentyltriazolo-pyrimidine (CPTP) S F OH Direct acting Not a pro-drug; does not require metabolic activation Rapid onset of inhibitory effect on the P2Y 12 receptor Greater inhibition of platelet aggregation than clopidogrel Reversibly bound Degree of inhibition reflects plasma concentration Faster offset of effect than clopidogrel Functional recovery of circulating platelets within ~48 hours

PLATO study design NSTE-ACS (moderate-to-high risk) (if primary PCI) -treated or -naive; randomised within 24 hours of index event (N=18,624) (n=9291) If pre-treated, no additional loading dose; if naive, standard 300 mg loading dose, then 75 mg qd maintenance; (additional 300 mg allowed pre PCI) (n=9333) 180 mg loading dose, then 90 mg bid maintenance; (additional 90 mg pre-pci) 6 12-month exposure Primary endpoint: CV death + MI + Stroke Primary safety endpoint: Total major bleeding

PLATO main endpoints Primary efficacy endpoint Primary safety endpoint 13 15 K-M estimated rate (% per year) 12 11 10 9 8 7 6 5 4 3 2 1 11.7 9.8 HR 0.84 (95% CI 0.77 0.92), p=0.0003 K-M estimated rate (% per year) 10 5 11.58 11.20 HR 1.04 (95% CI 0.95 1.13), p=0.434 0 0 No. at risk 0 2 4 6 8 10 12 Months 9,333 8,628 8,460 9,291 8,521 8,362 8,219 6,743 5,161 4,147 8,124 6,743 5,096 4,047 0 2 4 6 8 10 12 Months 9,235 7,246 6,826 6,545 5,129 3,783 3,433 9,186 7,305 6,930 6,670 5,209 3,841 3,479 Wallentin et al., New Eng J Med. 2009;361:1045 1057

and primary PCI Primary PCI is the optimal reperfusion therapy for Patients with and planned primary PCI particularly require urgent and effective blockade of the P2Y 12 platelet receptor and also are potentially at greater risk of side effects from new therapies Therefore, the objective of this predefined analysis of the PLATO trial was to investigate the efficacy and safety of ticagrelor versus clopidogrel in patients with intended for reperfusion with primary PCI

Patient disposition N/UA/other: 10,194 patients 18,758 patients enrolled in PLATO 18,624 patients randomized : 8,430 patients 134 patients not randomized Randomized to ticagrelor: efficacy population N= 4,201 Randomized to clopidogrel: efficacy population N= 4,229 Safety population N=4,165 No intake of study medication: 36 patients No intake of study medication: 48 patients Safety population N=4,181

PLATO population Inclusion criteria Hospitalization for ST-segment elevation ACS, with onset during the previous 24 hours with either of the following Persistent ST-elevation and planned primary PCI New or presumed new LBBB and planned primary PCI Or final diagnosis of Main exclusion criteria Contraindication to clopidogrel Fibrinolytic therapy within 24 hours prior to randomization Need for oral anticoagulation therapy as acute complication of PCI or PCI performed before the first study dose Increased risk of bradycardic events (e.g. no pacemaker and known sick sinus syndrome, 2nd degree A-V block, 3 rd degree A-V block or previous documented syncope suspected to be due to bradycardia) Concomitant therapy with strong CYP3A inhibitors or inducers

Baseline and index event characteristics Characteristic (n=4,201) (n=4,229) Median age, years 59 59 Women, % 24.1 23.5 CV risk factors, % Habitual smoker Hypertension Dyslipidemia Diabetes mellitus History, % Myocardial infarction Percutaneous coronary intervention Coronary-artery bypass graft ECG findings at entry, % Persistent ST-segment elevation 1mm Left bundle branch block Other* 45.5 59.3 38.7 19.6 13.5 8.8 2.6 81.3 8.0 10.7 44.3 57.8 39.2 21.1 13.8 7.9 2.7 80.6 9.0 10.3 +* Final diagnosis of

Study medication and procedures (n=4,201) (n=4,229) Start of randomized treatment Median time after start of chest pain, hours 5.6 5.8 Premature discontinuation of study drug, % 19.5 18.9 Invasive procedures at index hospitalization, % Coronary angiography PCI during index hospitalization CABG during index hospitalization Received at least one stent, % Bare metal stent only Drug-eluting stent (at least one) Open-label clopidogrel pre-randomization, % None 75 mg 300 mg 600 mg Total clopidogrel (OL + IP)* pre-randomization to 24 h, % 300 mg 600 mg * Includes placebo in the arm 92.6 80.6 2.2 74.3 57.9 16.1 56.5 4.8 18.1 20.7 65.2 34.8 92.8 80.0 2.9 74.2 57.6 16.3 55.5 5.1 18.6 20.8 65.4 34.6

Co-medication Medication Anti-thrombotic treatment in hospital, % Aspirin prior to index event Aspirin from index event to discharge Unfractionated heparin Low molecular weight heparin Fondaparinux Bivalirudin GPIIb/IIIa inhibitor from index event to randomization (n=4,201) 21.4 99.0 66.3 45.8 1.8 1.3 34.7 (n=4,229) 20.7 98.8 65.8 46.1 1.7 1.4 35.2 Other medication in hospital or at discharge, % Beta-blockade ACE inhibition and/or angiotensin-ii receptor blocker Cholesterol lowering (statin) Calcium-channel blocker Diuretic Proton pump inhibitor 85.8 86.0 94.8 17.1 36.2 49.1 86.2 85.9 95.1 17.1 35.4 49.1

Primary endpoint: CV death, MI or stroke 12 11 11.0 K-M estimated rate (% per year) 10 9 8 7 6 5 4 3 2 1 HR: 0.85 (95% CI = 0.74 0.97), p=0.02 9.3 0 No. at risk 0 1 2 3 4 5 6 7 8 9 10 11 12 Months 4,201 4,229 3,887 3,892 3,834 3,823 3,732 3,011 3,730 3,022 2,297 2,333 1,891 1,868

Primary efficacy endpoint in selected pre-defined subgroups Characteristic Hazard Ratio (95% CI) Total Patients KM % at Month 12 Ti. Cl. HR (95% CI) p-value (Interaction) Overall treatment effect Primary Endpoint 8,430 9.3 11.0 0.85 (0.74, 0.97) Definition of * Persist. ST-segment elev. 6,284 8.9 10.4 0.87 (0.74, 1.02) LBBB 720 14.5 14.5 0.89 (0.59, 1.34) Final diagnosis (only) 886 8.4 12.5 0.67 (0.44, 1.02) 0.49 Intended clop dose 24h post first dose 300 mg 600 mg 5,505 10.1 11.9 0.84 (0.71, 0.99) 2,922 7.9 9.3 0.86 (0.67, 1.11) 0.90 Time from index event to therapy <12 hours 6,072 8.3 9.5 0.86 (0.73, 1.03) 12 hours 2,270 12.0 14.2 0.85 (0.67, 1.07) 0.89 0.2 0.5 1.0 2.0 better better *Patients with LBBB and ST-elevation were classified as LBBB

Hierarchical testing of major efficacy endpoints Endpoint* (n=4,201) (n=4,229) HR for ticagrelor (95% CI) p-value Primary endpoint, % CV death + MI + stroke 9.3 11.0 0.85 (0.74 0.97) 0.02 Secondary endpoints, % Total death + MI + stroke 9.7 11.5 0.84 (0.73 0.96) 0.01 CV death + MI + stroke + ischaemia + TIA + arterial thrombotic events 13.4 15.4 0.86 (0.76 0.96) 0.01 MI 4.7 6.1 0.77 (0.63 0.93) 0.01 CV death 4.5 5.4 0.84 (0.69 1.03) 0.09 Stroke 1.6 1.0 1.45 (0.98 2.17) 0.07 All-cause mortality 4.9 6.0 0.82 (0.68 0.99) 0.04 The percentages are K-M estimates of the rate of the endpoint at 12 months. Patients could have had more than one type of endpoint. By univariate Cox model

CV death/total MI 11 10 10.3 K-M estimated rate (% per year) No. at risk 9 8 7 6 5 4 3 2 1 0 HR 0.81 (95% CI = 0.70 0.93), p=0.004 0 1 2 3 4 5 6 7 8 9 10 11 12 Months 4,201 3,912 3,862 3,759 3,038 2,321 1,914 4,229 3,908 3,841 3,751 3,043 2,350 1,881 8.3

All cause mortality 7 K-M estimated rate (% per year) 6 5 4 3 2 1 0 No. at risk HR 0.82 (95% CI = 0.68 0.99), p=0.04 0 1 2 3 4 5 6 7 8 9 10 11 12 Months 4,201 4,005 3,962 3,876 3,150 2,413 1,993 4,229 4,029 3,989 3,912 3,195 2,471 1,980 6.0 4.9

Stent thrombosis (as per ARC definitions)* (n=4,201) (n=4,229) HR for ticagrelor (95% CI) p-value Definite 1.6 2.5 0.61 (0.42 0.87) 0.01 Probable or definite 2.5 3.6 0.69 (0.52 0.92) 0.01 Possible, probable, or definite 3.2 4.4 0.73 (0.56 0.94) 0.02 Time-at-risk is calculated from the date of first stent insertion in the study or date of randomization *Cutlip et. al., Circulation. 2007;115:2344 2351 By univariate Cox model

Primary safety event: major bleeding K-M estimated rate (% per year) 10 8 6 4 2 9.3 9.0 No. at risk 0 HR 0.96 (95% CI = 0.83 1.12), p=0.63 0 1 2 3 4 5 6 7 8 9 10 11 12 Months 4,165 3,431 3,254 3,137 2,440 1,786 1,640 4,181 3,430 3,297 3,159 2,441 1,804 1,635

Total major bleeding 12 11 NS K-M estimated rate (% per year) 10 9 8 7 6 5 4 3 2 1 0 9.0 9.3 PLATO major bleeding 6.0 NS 6.4 TIMI major bleeding Major bleeding and major or minor bleeding according to TIMI criteria refer to non-adjudicated events analysed with the use of a statistically programmed analysis in accordance with definition described in Wiviott SD et al. New Eng J Med. 2007;357:2001 15; NS = not significant 7.3 NS 7.8 Transfusion Any blood product NS 4.5 4.9 PLATO lifethreatening/ fatal bleeding NS 0.3 0.1 Fatal bleeding

Other findings All patients Dyspnoea, % (n=4,165) (n=4,181) p-value * Any 12.9 8.3 <0.0001 Requiring discontinuation of study treatment 0.5 0.1 0.0003 Bradycardia-related events, % Bradycardia 4.6 4.9 0.57 Pacemaker placement 1.2 1.0 0.35 Syncope 1.0 0.8 0.35 Heart block 1.0 0.9 0.82 * Fisher s exact test

Conclusions Reversible, more intense P2Y 12 receptor inhibition for one year with ticagrelor in comparison with clopidogrel in patients with intended for reperfusion with primary PCI provides Reduction in composite of CV death, MI or stroke Reduction in MI and stent thrombosis Reduction in total mortality No increase in the risk of major bleeding The NNT (number needed to treat) to avoid one primary endpoint (CV death, MI or stroke) is 59 The mortality reduction is afforded on top of modern care may become a new standard of care for the management of patients with intended for primary PCI